Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:Q9UIJ5 (
Rec
)
58,342
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of cyclosporine and metabolite 17 (M17) as well as other CsA-related compounds (CsG, dihydro-CsC, dihydro-CsD, CsH, B5.49, and H7.94) was tested on T lymphocyte clone proliferation. In these experiments, antigen and interleukin 2 (IL-2) dependent long-term T lymphocyte clones derived from a rejected human kidney graft infiltrate were used. They were specifically committed (proliferation and cytotoxicity) for the donor
Epstein
-Barr virus (EBV)-transformed cells. CsA strongly inhibited clone T cell proliferation induced by the antigen. Inhibition of antigen-driven proliferation was reversed by pure recombinant IL-2 (rec-IL-2) only when low amounts of CsA (less than 25 ng/ml) were used, whereas this lymphokine was ineffective at higher but still pharmacological CsA concentrations (50-500 ng/ml). Increasing
rec
-IL-2 concentrations did not modify this finding. In addition, CsA, did not inhibit the growth signal(s) induced by
rec
-IL-2/IL-2 receptor interactions when R-IL-2 is pre-expressed on clone cells. M17 was far less effective in inhibiting antigen-induced clone cell proliferation (50% inhibition at 16 ng/ml versus 500 ng/ml with, respectively, CsA and M17) but was nevertheless inhibitory. This observation, if extended to other metabolites, could be important for interpretation of the relevance of "CsA" concentration through radio-immunoassay monitoring of recipients' blood. Although CsA appeared to display the major inhibitory effect, dihydro-CsC and CsG, as well as B5.49 and H7.94 CsA-related compounds, also exhibited strong activity. Dihydro-CsD was less inhibitory, and CsH had no effect.
...
PMID:Effect of cyclosporine, cyclosporine metabolite 17, and other cyclosporine-related compounds on T lymphocyte clones derived from rejected human kidney grafts. I. Inhibition of proliferation. 332 90
Two areas of current research have the potential to improve the quality of virological surveillance of measles. A new highly sensitive cell line that does not secrete
Epstein
Barr virus is being tested as a replacement for B95a cells. Also, alternative protocols that simplify the logistics of specimen collection, such as dried blood spots, are being evaluated. A list of literature references about measles molecular epidemiology is available from WHO upon request. Periodic updates about the genetic characteristics of currently circulating strains and new genotypes will be published in the WHO Measles Bulletin and will be available via the Internet from the WHO strain bank at CDC.
Wkly Epidemiol
Rec
2001 Aug 17
PMID:Nomenclature for describing the genetic characteristics of wild-type measles viruses (update). 1156 58
Overexpression of miR-155 in nasopharygeal carcinoma (NPC) is partly driven by
Epstein
-Bar virus infection. However the role of miR-155 in NPC oncogenesis is unclear. This study showed that miR-155 inhibitor could inhibit the cell migration in NPC cell lines.
ZDHHC2
was identified as a direct target of miR-155 and downregulation of
ZDHHC2
prompted cell migration in NPC. Furthermore, reduced
ZDHHC2
expression was associated significantly with metastasis and poor survival of NPC patients. Collectively, inhibition of miR-155 suppresses cell migration in NPC through targeting
ZDHHC2
. The potential of miR-155 and
ZDHHC2
as therapeutic targets in NPC should be further investigated.
...
PMID:Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. 2630 99